soluble fms-like tyrosine kinase 1

soluble fms-like tyrosine kinase 1

,

sFlt-1

An antiangiogenic protein found in the serum of women who subsequently develop preeclampsia. It may contribute to the development of this syndrome.
References in periodicals archive ?
Studies have speculated that this leads to placental hypoxia, reduced placental perfusion, and the consequent release of placental soluble factors such as soluble fms-like tyrosine kinase 1 (sFlt-1) and soluble endoglin (sEng) (11,12).
Excess placental soluble fms-like tyrosine kinase 1 (sFlt1) may contribute to endothelial dysfunction, hypertension, and proteinuria in preeclampsia.
Soluble FMS-like tyrosine kinase 1 is an angiogenic factor that enters the maternal bloodstream and binds vascular endothelial growth factor (VEGF).
Statins, meanwhile, have been shown to prevent or reverse angiogenic imbalance by promoting the release of vascular endothelial growth factor and placental growth factor and by suppressing the production of soluble FMS-like tyrosine kinase 1 and soluble endoglin.
Pre- and postoperative circulating levels of VEGF, PlGF and sFlt-1 in both groups PP group Control group (mean[+ or -]SD) (mean[+ or -]SD) p (n=22) (n=22) VEGF, (pg/mL) Preop 39.18[+ or -]11.98 85.87[+ or -]18.05 <0.001 Postop 143.73[+ or -]47.47 101.61[+ or -]31.39 0.001 PlGF, (pg/mL) Preop 39.94[+ or -]12.00 76.65[+ or -]21.49 <0.001 Postop 104.88[+ or -]17.06 107.52[+ or -]30.65 >0.05 sFlt-1, (ng/mL) Preop 236.28[+ or -]48.44 276.30[+ or -]77.72 <0.05 Postop 597.34[+ or -]55.38 328.53[+ or -]79.80 <0.001 PP: placenta percreta; SD: standart deviation; VEGF: vascular endothelial growth factor; PlGF: placental growth factor; sFlt-1: soluble fms-like tyrosine kinase 1 TABLE 3.
High circulating concentrations of antiangiogenic factors such as soluble fms-like tyrosine kinase 1 (sFlt1) [3] and low concentrations of proangiogenic factors such as placental growth factor (PIGF) released by the placenta contribute to systemic endothelial dysfunction and the development of the maternal hypertensive syndrome (2).
Merchan et al., "Excess placental soluble fms-like tyrosine kinase 1 (sFlt1) may contribute to endothelial dysfunction hypertension, and proteinuria in preeclampsia," Journal of Clinical Investigation, vol.
There was no association between the levels of vitamin D and of two angiogenic factors that have been previously implicated in the development of preeclampsia, soluble FMS-like tyrosine kinase 1 (sFlt-1) and placental growth factor (PlGF).
Both new studies examined pregnant women's blood concentrations of placental growth factor (PlGF) and soluble fms-like tyrosine kinase 1 (sFlt1).
Soluble fms-like tyrosine kinase 1 (sFlt1), endoglin and placental growth factor (PlGF) in preeclampsia among high risk pregnancies.
Moreover, the increase in TSH level was significantly associated with increasing quartiles of soluble fms-like tyrosine kinase 1 (sFlt-1), which "may be responsible for the clinical phenotype of preeclampsia," the investigators wrote.
The gene encoding a protein called soluble fms-like tyrosine kinase 1 (sFlt1) was overactive in the preeclamptic placentas.
Full browser ?